hepatitis B

10 · 20 / page

Ask MedXY AI

Latest news

Tag

GastroenterologyHBsAg lossNucleos(t)ide analogue withdrawal

Enhancing Hepatitis B Treatment: Pegylated Interferon After Nucleos(t)ide Withdrawal Boosts HBsAg Loss in HBeAg-Negative Patients

By MedXY|Aug 7, 2026

Adjuvant pegylated interferon following nucleos(t)ide analogue withdrawal in HBeAg-negative chronic hepatitis B significantly increases HBsAg loss rates and reduces severe hepatic flares over three years compared to withdrawal alone.

Long-term Risk of Hepatocellular Carcinoma After Clearance of Hepatitis B Surface Antigen

Gastroenterologychronic hepatitis B

hepatitis B

Latest news

Enhancing Hepatitis B Treatment: Pegylated Interferon After Nucleos(t)ide Withdrawal Boosts HBsAg Loss in HBeAg-Negative Patients

Long-term Risk of Hepatocellular Carcinoma After Clearance of Hepatitis B Surface Antigen

Significant Barriers and Pandemic Setbacks: Why Hepatitis B Birth Dose Coverage Remains Low in The Gambia

Where Are People with Chronic Hepatitis B Lost? Global review shows major gaps after diagnosis — especially outside specialist care

Peginterferon Add‑On to siRNA JNJ‑73763989 Yields Deep HBsAg Declines but Not Durable Off‑Therapy Cure in HBeAg‑Positive CHB: Phase 2 REEF‑IT Results

Not All ‘Indeterminate’ HBV Is Equal: Specific Indeterminate Types Carry Markedly Higher Long‑Term HCC Risk

Targeting HBx-Induced HSPB1: A Novel Approach to Combat Chronic Hepatitis B and Boost Liver Immunity

PegIFN Alpha-2a Therapy Reduces Relapse Risk after NUC Discontinuation in HBeAg-Negative Chronic Hepatitis B: Insights from a Randomized Controlled Trial

Enhanced Diagnostic and Prognostic Utility of the China-CLIF Framework for Acute-on-Chronic Liver Failure Across Diverse Aetiologies

From Silent Struggles to Serious Threats: Understanding Your Liver’s Journey from Hepatitis to Cancer